After five years at No. 1 in Surescripts’ Safe-Rx Awards, Massachusetts drops to No. 2 in the rankings of highest e-prescribing use in the nation during 2011.
Surescripts announced that Minnesota achieved the highest rate of e-prescribing use in the nation during 2011 to capture the No. 1 ranking in its seventh annual Safe-Rx Awards. After a five-year run at No. 1, Massachusetts falls to No. 2.
The rankings are determined by an analysis of data that measures electronic prescribing use by physicians, pharmacies and payers in each state. The top 10 states with the highest rates of e-prescribing, according to Surecripts, are:
1. Minnesota
2. Massachusetts
3. South Dakota
4. Delaware
5. New Hampshire
6. Iowa
7. North Carolina
8. Maine
9. Vermont
10. Michigan
Growth in the adoption and use of e-prescribing – which includes prescription routing, utilization of benefit information and utilization of medication history – created the most changes in the rankings over its seven-year history. According to Surescripts, the data indicates that state and federal initiatives to increase the adoption and use of e-prescribing by healthcare providers are significant drivers in e-prescribing’s growth.
Highlights from the rankings include:
Go back to the Managed Healthcare Executive eNews newsletter.
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
The Relationship Between ILD and MDA5 Antibody-Positive DM
May 2nd 2024Rapidly progressing interstitial lung disease in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is known for its high death rate because it worsens quickly and causes breathing difficulties within three months of initial lung symptoms. However, there isn't much information about the timing between the diagnosis of ILD and MDA5 antibody-positive DM because most research focuses on either the frequency or the death rates rather than the timing of onset.
Read More